Medistep HealthcareShare price, financial results, shareholding and management
- Market cap
- ₹27 cr
- Stock P/E
- 4.5peers 44.2
- Book value
- ₹26.6
- Price to book
- 0.71
- EV / operating profit
- 3.8
- Market cap to sales
- 0.38
- ROCE · FY26
- 27.0%
- ROE · FY26
- 21.7%
- ROE, 3-year average
- 25.1%
- Operating margin · FY26
- 11.6%peers 15.4%
- Sales growth, 3 years
- +42.7%
- Profit growth, 3 years
- +44.4%
- Debt to equity
- 0.14peers 0.26
- Borrowings
- ₹5.2 cr
- Interest cover
- 33.0×
- Cash from business / op. profit
- -236%
- Debtor days
- 203
- Pledged
- 0.00%
- Promoter holding
- 68.96%
- Change in promoter holding
- 0.00 pts
- Shareholders
- 514
- 52-week high / low
- ₹30 / ₹17
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Medistep Healthcare share price chart
Close on 19 Nov 2026 · +3.85% on the day · Vol 21,000
Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 19 Nov 2026
- 1 month
- -11.7%
- 3 months
- +1.9%
- 6 months
- -10.0%
- 1 year
- -35.7%
- Since IPO
- -56.0%
- Traded a day, 20 days
- ₹0.02 cr
- Taken for delivery
- 91%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +43% | +44% |
| 3 years, a year | - | - |
| Latest half, H2 FY26 | +26% | +22% |
About Medistep Healthcare: business, products and customers
Medistep Healthcare makes sanitary pads and an energy drink powder in Gujarat, and trades medicines, supplements, hygiene goods and surgical supplies to distributors and stockists. Its shares trade on NSE Emerge.
The company was formed in June 2023 and took over MG Pharma, a trading business owned by promoter Prajapati Hetalben Girdharilal, in July 2023. It started making DryStep sanitary pads and VitaStep-Z energy powder in January 2024 at a small unit in Bareja, Kheda, Gujarat. Alongside its own products it trades pharmaceutical formulations, nutraceuticals, intimate care products and surgical supplies such as syringes, needles and masks.
Most sales are traded goods, and almost all revenue goes through distributors and stockists rather than pharmacies or hospitals. Trading earns a thin margin, so the small manufacturing line carries most of the profit: in FY25 it made about a quarter of revenue but nearly four fifths of segment profit. Revenue and margin therefore move with how much of the mix is the company's own pads and powder.
Read more about the business
Distributors are given long credit, so profit has not turned into cash: trade receivables roughly doubled in FY26 and the company drew a bank cash credit line, while most of the IPO money was set aside for working capital. The offer document names Achyut Healthcare and Fabino Enterprises as listed companies in a similar line of healthcare products and trading.
From the offer document (business, capacity, customers, objects of the issue and peers), the FY26 annual report (directors' report, financial statements and notes) and the FY25 annual report (related party note).
Read the deeper study ↓In its favour
- Sales have grown fast: 43% a year last year.
- It earns a high return on the money it uses: ROCE 27% in FY26.
- It has little debt for its size: debt to equity 0.14.
- The promoters own a large part of the company: 68.96%.
To watch
- Collection of the ₹39.4 cr owed by customers at March 2026 (Annual report FY26, p.67).
- Use of the IPO money for working capital and the new machinery for new products at Bareja (Offer document, p.91 and p.95).
- Any loans, guarantees or investments made under the ₹100 cr limit put to shareholders in FY26 (Annual report FY26, p.17).
- Progress towards the stated turnover goal of ₹250 cr by FY2030 (Offer document, p.146).
- Customers take longer to pay than before: 203 days in FY26, against 159 in FY24.
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Medistep Healthcare revenue and profit growth
Half-yearly results · Profit and lossSales have grown fast. Last year profit grew roughly in step with sales.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before.
Medistep Healthcare half-yearly results
SME companies report every six months · ₹ crore
| H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|
| Sales | 21.25 | 28.40 | 35.07 | 35.76 |
| Expenses | 18.96 | 25.09 | 31.08 | 31.50 |
| Operating profit | 2.29 | 3.31 | 3.99 | 4.26 |
| OPM | 10.8% | 11.7% | 11.4% | 11.9% |
| Interest | 0.02 | 0.01 | 0 | 0.25 |
| Depreciation | 0.02 | 0.02 | 0.01 | 0.01 |
| Profit before tax | 2.25 | 3.28 | 3.97 | 4.03 |
| Net profit | 1.69 | 2.46 | 2.97 | 3.01 |
Medistep Healthcare profit and loss
Full years to March, FY24 to FY26 · ₹ crore, consolidated where reported
| FY24 | FY25 | FY26 | |
|---|---|---|---|
| Sales | 31.60 | 49.65 | 70.83 |
| Expenses | 27.64 | 44.04 | 62.58 |
| Operating profit | 3.96 | 5.61 | 8.25 |
| OPM | 12.5% | 11.3% | 11.6% |
| Other income | 0.01 | 0 | 0.02 |
| Interest | 0.06 | 0.04 | 0.25 |
| Depreciation | 0.02 | 0.03 | 0.03 |
| Profit before tax | 3.89 | 5.54 | 8 |
| Tax rate | 25.2% | 25.3% | 25.2% |
| Net profit | 2.91 | 4.14 | 5.98 |
| EPS ₹ | 5.94 | 3.96 | 4.68 |
| Dividend payout | 0.0% | 0.0% | 0.0% |
Medistep Healthcare profitability
Margins and returns on capitalLast year the company kept about as much from each rupee of sales as the year before. It earns a high return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY24 | FY25 | FY26 | |
|---|---|---|---|
| Operating margin | 12.5% | 11.3% | 11.6% |
| Tax rate | 25.2% | 25.3% | 25.2% |
| ROCE | · | 37.2% | 27.0% |
| ROE | · | 28.5% | 21.7% |
| Dividend payout | 0.0% | 0.0% | 0.0% |
Medistep Healthcare debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown fast. It borrowed much more last year. Its loans are smaller than its own money. Last year the business used more cash than it brought in. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.
Bars below the line are cash going out.
Medistep Healthcare balance sheet
At each 31 March · ₹ crore
| FY24 | FY25 | FY26 | |
|---|---|---|---|
| Equity capital | 4.90 | 10.47 | 14.21 |
| Reserves | 6.79 | 6.89 | 23.62 |
| Net worth | 11.69 | 17.36 | 37.82 |
| Borrowings | 0.33 | 0.64 | 5.18 |
| Other liabilities | 2.93 | 5 | 7.30 |
| Total liabilities | 14.95 | 23 | 50.30 |
| Fixed assets | 0.15 | 0.14 | 0.12 |
| Capital work in progress | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| Other assets | 14.80 | 22.86 | 50.18 |
| Receivables | · | · | 39.39 |
| Inventory | · | · | 6.18 |
| Cash | · | · | 0.61 |
| Trade payables | · | · | 3.65 |
Medistep Healthcare cash flow
₹ crore
| FY24 | FY25 | FY26 | |
|---|---|---|---|
| Cash from operations | -7.11 | 0.02 | -19.48 |
| Cash from investing | -0.15 | 0 | -0.01 |
| Cash from financing | 7.24 | 1.28 | 18.79 |
| Net cash flow | -0.02 | 1.30 | -0.70 |
| Capital spending | · | · | 0.01 |
Working capital
Days
| FY24 | FY25 | FY26 | |
|---|---|---|---|
| Debtor days | 159 | 148 | 203 |
| Inventory days | 12 | 9 | 37 |
| Days payable | 19 | 21 | 22 |
| Cash conversion cycle | 152 | 137 | 218 |
| Working capital days | 134 | 117 | 191 |
Medistep Healthcare peers and competitors
Listed SME companies in the same industryBy sales, Medistep Healthcare is number 4 of the 8 listed SME companies in personal products.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Anondita Medicare | 1,903 | 56.0 | 137 | 34 | 37.0% | 0.26 |
| H. R. Hygiene Products | 139 | 12.6 | 130 | 11 | 14.0% | 0.51 |
| Recode Studios | 486 | 44.2 | 80 | 11 | 21.0% | 0.30 |
| Medistep Healthcare | 27 | 4.5 | 70.8 | 6 | 11.6% | 0.14 |
| Aakaar Medical Technologies | 101 | 15.1 | 67 | 6.6 | 15.4% | 0.34 |
| Macobs Technologies | 195 | 67.2 | 41.4 | 2.9 | 8.3% | 0.06 |
| Ravelcare | 68 | 13.1 | 27 | 5.2 | 26.2% | 0.00 |
| Novateor Research Laboratories | 23 | 227.0 | 3.8 | 0.1 | -2.6% | 0.09 |
| Median of the 7 others | 139 | 44.2 | 67 | 6.6 | 15.4% | 0.26 |
Medistep Healthcare shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company. Big foreign and Indian funds own very little. The number of shareholders is about the same.
Medistep Healthcare shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Aug 25 | Sep 25 | Mar 26 | |
|---|---|---|---|
| Promoters | 68.96% | 68.96% | 68.96% |
| Indian institutions (DIIs) | 0.00% | - | - |
| HNIs (over ₹2 lakh each) | 4.69% | 8.07% | 10.56% |
| Small holders (up to ₹2 lakh) | 22.59% | 18.54% | 16.98% |
| Companies and others | 3.76% | 4.43% | 3.50% |
| Number of shareholders | 525 | 578 | 514 |
The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.
Medistep Healthcare study: the business from its own documents
Read from 3 of the company's own documentsMedistep Healthcare so far
From the company's own record
- June 2023Company formed
- 18 Aug 2025Listed on NSE Emerge at ₹43
- 31 March 2026Promoters at 68.96%
- 18 Aug 2025Highest close since listing, ₹50.35
Medistep Healthcare key facts from the filings
Each figure with the document it comes from
- FY26 revenue
- ₹70.8 cr
- Up from ₹49.7 cr in FY25.Annual report FY26, p.19
- FY26 profit after tax
- ₹6.0 cr
- Up from ₹4.1 cr in FY25.Annual report FY26, p.19
- Owed by customers
- ₹39.4 cr
- Trade receivables at March 2026, against ₹20.1 cr a year earlier.Annual report FY26, p.67
- Own products
- 26.5%
- Share of FY25 revenue from pads and powder the company makes; the rest is trading.Offer document, p.144 and p.145
- Profit from manufacturing
- ₹4.8 cr
- FY25 segment profit from manufacturing, against ₹1.3 cr from trading on far larger sales.Offer document, p.248
Show 5 more facts
- Top ten customers
- 89.3%
- Share of FY25 revenue, with no binding agreements in place.Offer document, p.36 and p.153
- Through distributors
- 96%
- Share of FY25 revenue sold to distributors and stockists. Reported results; our arithmetic.Offer document, p.145
- Pad capacity used
- 60.6%
- Use of the doubled pad line, 25.92 lakh packets per half year, from October 2024 to March 2025.Offer document, p.168
- Bank borrowing
- ₹4.9 cr
- State Bank of India cash credit at March 2026; there was almost no bank debt a year earlier.Annual report FY26, p.65
- IPO money for working capital
- ₹12.3 cr
- Of net proceeds of ₹14.5 cr from the issue at ₹43 a share; ₹0.5 cr was for new machinery.Offer document, p.91 and p.26
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
The offer document sets a goal of ₹250 cr of turnover by the end of FY2030. The company says it will install new machinery for new products at Bareja from the IPO money and expects to run it at full capacity. In FY26 shareholders were asked to raise the limit on loans, guarantees and investments the board may make to ₹100 cr, which the company says is for its growth plans.
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
The company earns most of its profit from the pads and powder it makes, and adds a thin margin on a much larger trading business.
Its weak spot is cash: a few distributors take most of the goods on long credit, so profit has been tied up in money owed.
WatchCan it set its own prices?It makes everyday hygiene products and trades common medicines, where price is the main way to compete.
WatchHow strong is it against rivals?A small regional maker and trader with one compact unit and a thin team.
WatchWho are its customers?A few distributors and stockists take nearly everything, without contracts, and the list changes a lot from year to year.
WatchDoes it need a lot of money?The plant costs little, but the credit given to distributors needs a lot of money.
AverageCan it keep finding new work?The pad line has spare room and new machinery for new products is planned, but there is no order book.
AverageDo good and bad years swing a lot?Demand for hygiene products and medicines is steady, though the energy powder sells mainly in summer.
Who runs Medistep Healthcare?
Promoters, directors and officers; tap a name for the background
GLGirdhari Lal PrajapatPromoter, Founder and Managing Director · holds 9.94%
Bachelor of Pharmacy from Rajasthan University of Health Sciences, Jaipur, with over 12 years in the pharmaceutical industry. Started in the production department at Cadila Pharmaceuticals, then worked in sales and marketing and as a pharmacist at AIMS Hospital, Paldi, Ahmedabad. A director since incorporation and Managing Director from February 2024, paid ₹6 lakh a year.
Offer document, p.188, p.190 and p.193PHPrajapati Hetalben GirdharilalPromoter and Non-Executive Director · holds 50.08%
Six years in pharmaceutical sales, stock and market operations; a sales executive at Nand Kishor Medical and General Store from 2014 to 2016, then owner of MG Pharma, the business the company took over. The offer document states Prajapati Hetalben Girdharilal is the wife of Girdhari Lal Prajapat.
Offer document, p.189, p.190 and p.192DVDabhi Vipul GobarbhaiPromoter and Executive Director · holds 8.94%
Bachelor of Ayurvedic Medicine and Surgery from Gujarat Ayurved University, with over 19 years of hospital practice at Hope Neurocare, Rudraksh Institute of Medical Science and Narol ICU and Trauma Center, Ahmedabad. A director since incorporation; draws no pay.
Offer document, p.189, p.191 and p.193JPJagdish PrajapatiPromoter and Chief Financial Officer · holds Nil
Bachelor of Commerce from Gujarat University and CA Intermediate, with six years in accounts, finance and taxation at Virtual Accounting Solutions LLP, Lalit K Sharma and Company and A and D Consulting. CFO since February 2024.
Offer document, p.26, p.199 and p.200KAKhoda Anandbhai JitendrabhaiIndependent Director
Medical degree from Vikram University, Ujjain, with over 15 years in healthcare; partner of Astha Hospital, Bareja and a director of Rudra Super Speciality Hospital Private Limited.
Offer document, p.190 and p.191DKDodiya Kapilbhai RaysinhbhaiIndependent Director
Medical degree from Hemchandracharya North Gujarat University, Patan, with eight years in hospitals; partner of Jeevandeep Hospital, Matar and Shree Krishna Multispeciality Hospital, Bareja.
Offer document, p.189 to p.191Medistep Healthcare latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹35.8 cr (+26%), net profit ₹3 cr (+22%) on H2 FY25.
- Shareholding, 31 March 2026: promoters unchanged at 68.96%.
Medistep Healthcare announcements
14 on record, latest first; each opens the filing on the exchange
- Quarterly Compliance Report on Corporate governance - within 21 days from the enMedistep Healthcare Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Quarter ended September, 2026PDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- Shareholders meetingSrutinizers report of Annual General Meeting held on September 17, 2026. Further, the company has informed the Exchange regarding voting resultsPDF ↗
- Shareholders meetingProceedings of Annual General Meeting held on September 17, 2026PDF ↗
- Copy of Newspaper PublicationCopy of Newspaper PublicationPDF ↗
- Change in Managementchange in ManagementPDF ↗
- Updates'Intimation of book closure for financial year 2025-2026'PDF ↗
- Outcome of Board MeetingHeld on August 24, 2026PDF ↗
- Shareholders meetingNotice of to be held on September 17, 2026PDF ↗
- General UpdatesGeneral UpdatesPDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
Medistep Healthcare annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
- Offer document ↗read
Medistep Healthcare share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Medistep Healthcare's data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (1,42,09,546 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- ✓Earnings per share moves in line with profit across the years shown.
- ✓Revenue and profit are reported for every year shown, FY24 to FY26.
- iPrices run to the close on 12 Oct 2026, from the exchange's daily figures.
Questions people ask about Medistep Healthcare
What does Medistep Healthcare do?
Medistep Healthcare makes sanitary pads and an energy drink powder in Gujarat, and trades medicines, supplements, hygiene goods and surgical supplies to distributors and stockists. Its shares trade on NSE Emerge.
What is the share price of Medistep Healthcare?
₹18.9 at the close on 19 Nov 2026, from the exchange's daily figures.
What is the market cap of Medistep Healthcare?
₹27 cr at the close on 19 Nov 2026, on 1,42,09,546 shares.
What is the P/E of Medistep Healthcare?
4.5 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).
What are Medistep Healthcare's revenue and profit?
Revenue ₹71 cr and profit after tax ₹6 cr in FY26.
Who are the promoters of Medistep Healthcare?
Girdhari Lal Prajapat, Prajapati Hetalben Girdharilal, Dabhi Vipul Gobarbhai, Jagdish Prajapati; promoters held 68.96% at 31 March 2026.
What was the IPO price of Medistep Healthcare?
₹43 a share; it listed on 18 Aug 2025.
What is Medistep Healthcare's website?
www.medistephc.com
More SME companies like Medistep Healthcare
Other listed SME companies in personal products, the closest in size first, each read from its own documents.
- Novateor Research LaboratoriesNOVATEOR · BSE SME · Personal ProductsMarket cap ₹17 cr
- RavelcareRAVEL · BSE SME · Personal ProductsMarket cap ₹64 cr
- Aakaar Medical TechnologiesAAKAAR · NSE Emerge · Personal Products · listed 2025Market cap ₹94 cr
- H. R. Hygiene ProductsHRHYGIENE · BSE SME · Personal ProductsMarket cap ₹150 cr
- Macobs TechnologiesMACOBSTECH · NSE Emerge · Personal Products · listed 2024Market cap ₹186 cr
- Recode StudiosRECODE · BSE SME · Personal ProductsMarket cap ₹373 cr
Every listed SME company in Personal Products → · SME companies listed in 2025 →
Built from 2 annual reports, 1 offer document, 14 exchange announcements, 3 shareholding patterns and 3 years of reported results. Every figure carries its source; where the documents are silent, the page says so.